The North America NGS market was worth USD 1.53 billion by the end of 2021 is estimated to reach USD 3.33 billion by 2026, at a CAGR of 16.81% during the forecast period.
The significant factors that are propelling the growth of North America NGS market are increasing incidence of cancer, increasing applications of NGS in precision medicine and biomarker discovery. The rise in the adoption rate of NGS platforms for analysis and diagnostics of rare diseases and for identifying therapeutic targets, the emergence of rapid and advanced sequencing technologies, reduced costs of sequencing, growing demand for NGS methodologies in genomics research, and in clinical diagnosis are further driving the market.
Furthermore, growth in investments in R&D activities due to the high occurrence of cancer and infectious diseases and the development in Next-Generation Sequencing Bioinformatics equipment and the presence of the significant player in the region drives the market growth. On the other hand, usage of NGS in biomarker detection and precision medicine is likely to have a positive impact on the growth of North America next-generation sequencing market in the coming years.
The significant challenges that are restricting the growth of the North America NGS market are Expensive technologies that are not affordable due to budget limitations in developing economies, risks involved with genetic data.
This research report segmented and sub-segmented into the following categories:
Regionally, the U.S. NGS Market is dominating the NGS market in North America and is expected to maintain the trend during the forecast period owing to rapid developments in healthcare and particularly in the biotechnology field. Canada is displaying significant growth in recent years. It is likely to grow consistently during the forecast period owing to the research advancements and rising adoption of NGS products in hospitals and clinics.
In the United States NGS market contains all sequencing services directed with next-generation or third-generation platforms that use newer technology than old capillary electrophoresis (CE) sequencing. Services include project scoping, NGS sample preparation, and NGS-based sequencing runs with primary data output. The increasing number of Next Generation Sequencing new research activities carried out in Canadian universities is leading to the growth of the Next Generation Sequencing data analysis market in this region.
Companies playing a leading role in the North American NGS Market profiled in this report are Illumina Incorporated, Thermo Fischer Scientific, Life Sciences (Roche), Pacific Biosciences, Life Technologies Corp. (Thermo Fischer Scientific), Macrogen Inc., Partek Inc., Genomatix Software GmbH, Perkin Elmer inc., GATC Biotech Ag, Agilent Technologies Inc., Biomatters Ltd., CLC Bio (Qiagen), BGI (Beijing Genomics Institute), Oxford Nanopore Technologies Ltd., DNASTAR Inc., Knome Inc. and Qiagen N.V.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Product
5.1.1 Software
5.1.2 Services
5.2 By Technology
5.2.1 Whole Targeted Re-Sequencing
5.2.2 Genome Sequencing
5.2.3 De Novo Sequencing
5.2.4 Exome Sequencing
5.2.5 RNA-Seq
5.2.6 ChIP-Seq
5.2.7 Methyl-Seq
5.3 By Application
5.3.1 Diagnostics
5.3.2 Drug Discovery
5.3.3 Biomarker Discovery
5.3.4 Personalized Medicine
5.3.5 Agriculture and Animals Research
6.1 Introduction
6.2 United States
6.3 Canada
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Macrogen Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Thermo Fischer Scientific
8.3 Life Sciences (Roche)
8.4 Pacific Biosciences
8.5 Life Technologies Corp.
8.6 Partek Inc.
8.7 Genomatix Software GmbH
8.8 Perkin Elmer Inc.
8.9 GATC Biotech Ag
8.10 Agilent Technologies Inc.
8.11 Biomatters Ltd.
8.12 CLC Bio (Qiagen)
8.13 Pacific Biosciences
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
